-
IntroducedFeb 13, 2024
-
Passed House
-
Passed Senate
-
Signed into Law
Commissioner of human services authorized to provide separate reimbursement for biological products provided in the inpatient hospital setting as part of cell or gene therapy to treat rare diseases.
Last Action See all actions
House • Mar 18, 2024: Author added Hemmingsen-Jaeger
Latest Bill Text See all bill texts
Summary/Bill Text
Comments on HF 3664
Tweets
Whip Lists
Sponsors
- Hemmingsen-Jaegercosponsor
Votes
Actions
- Mar 18, 2024 | House
- Author added Hemmingsen-Jaeger
- Mar 13, 2024 | House
- Author added Nadeau
- Feb 26, 2024 | House
- Author added Reyer
- Feb 13, 2024 | House
- Introduction and first reading, referred to Health Finance and Policy
Bill Texts
Documents